Form 4: Director Eduardo Alfonso Receives Bausch + Lomb RSU Grant

Director Eduardo Alfonso acquired 15,842 restricted share units in Bausch + Lomb Corporation as part of an annual equity grant.

Summary

• Director Eduardo Alfonso was granted 15,842 restricted share units (RSUs) on May 26, 2026.
• The grant was issued under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan.
• Following this transaction, the director's total beneficial ownership of common shares increased to 31,072.
• The RSUs are scheduled to vest on the day before the next annual meeting of shareholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director compensation.

Positives

• Alignment of director interests with shareholders through equity-based compensation.
• Standard annual incentive grant indicates normal corporate governance practices.

Negatives

• None identified.

Risks

• Value of equity holdings is subject to market volatility of Bausch + Lomb common shares.

Future Outlook

The RSUs will vest on the date immediately preceding the next annual meeting of shareholders, at which point they will be settled in common shares.

Industry Context

StockSavvy.ai notes that annual equity grants to non-employee directors are a standard practice in the pharmaceutical and medical device industry to ensure long-term alignment between board members and shareholders.

Comparison to Industry Standards

• The grant structure is consistent with standard corporate governance practices for large-cap healthcare companies.
• The use of an Omnibus Incentive Plan is typical for publicly traded entities of this size.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard compensation event.

Next Steps

• Vesting of RSUs on the day prior to the next annual meeting of shareholders.

Key Dates

Keywords

Bausch + Lomb, BLCO, Form 4, Insider Trading, Director Compensation, Equity Grant